57th ASH Annual Meeting and Exposition (December 5-8, 2015): 902. Health Services and Outcomes Research – Malignant Diseases: Clinical Trials and Health Outcomes

Health Services and Outcomes Research – Malignant Diseases Oral and Poster Abstracts
Oral

Chapin Theater (W320), Level 3 (Orange County Convention Center)

Moderators:

Heather Jim, PhD, H. Lee Moffitt Cancer Center and Research Institute and William A. Wood, MD, MPH, University of North Carolina

Disclosures:

Wood: Inform Genomics: Consultancy ; Best Doctors: Consultancy .

10:30 AM

631

The Impact of Insurance Status at Diagnosis on Overall Survival in Chronic Myeloid Leukemia: A Population-Based Analysis

Ashley M. Perry, BS¹^*, Tao Zou, MD, PhD¹^*, Andrew M. Brunner, MD^1,2, Donna S Neuberg, ScD³ and Amir T. Fathi, MD¹

¹Massachusetts General Hospital, Boston, MA
²Dana-Farber Cancer Institute, Boston, MA
³Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

10:45 AM

632

Kimberley Blackwell¹^*, Ruslan Paltuev²^*, Roman Donskih³^*, Olga Burdaeva⁴^*, Elena Bit-Sava⁵^*, Tanveer Maksud⁶^*, Michael Jones⁷^*, Allen Nixon⁸^*, Maria J Vidal⁹^*, Roumen Nakov¹⁰^*, Pritba Singh¹⁰^*, Gregor Schaffer¹⁰^*, Pere Gascon¹¹ and Nadia Harbeck¹²^*

¹Duke University, Durham, NC
²Railway Clinical Hospital of OJSC "RZhD", St Petersburg, Russia
³Scientific Research Oncology Institute n.a. N.N. Petrov, St Petersburg, Russia
⁴Arkhangelsk Clinical Oncology Dispensary Oncology Research Center, Arkhangelsk, Russia
⁵Saint-Petersburg State Medical University n.a.acad. I.P. Pavlov, St Petersburg, Russia
⁶Bharat Cancer Hospital & Research Institute, Surat, India
⁷Jones Clinic, Germantown, TN
⁸Fowler Family Center for Cancer Care, Jonesboro, AR
⁹Hospital General Vall d’Hebron, Barcelona, Spain
¹⁰Hexal AG/Sandoz Biopharmaceuticals, Holzkirchen/Oberhaching, Germany
¹¹Hospital Clinic de Barcelona, Barcelona, Spain
¹²Breast Center, University of Munich, Munich, Germany

11:00 AM

633

Insurance Status, Marital Status and Income, but Not Race-Ethnicity Affect Outcomes of Younger Patients Diagnosed with Multiple Myeloma in the US

Luciano J Costa, MD, PhD¹ and Elizabeth E. Brown, PhD, MPH²

¹Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
²University of Alabama At Birmingham, Birmingham, AL

11:15 AM

634

Demographic Differences Between Unselected Patients and Participants of Multiple Myeloma Clinical Trials in the US: A Threat to External Validity

Luciano J Costa, MD, PhD¹, Parameswaran Hari, MD, MRCP, MS² and Shaji Kumar, MD³

¹Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
²Medical College of Wisconsin, Milwaukee, WI
³Division of Hematology, Mayo Clinic, Rochester, MN

11:30 AM

635

Eligibility Criteria Are Not Associated with Expected or Observed Adverse Events in Randomized Controlled Trials (RCTs) of Hematologic Malignancies

Abby Statler, MPH, MA¹^*, Tomas Radivoyevitch, PhD²^*, Caitlin Siebenaller, PharmD, BCOP³^*, Aaron T. Gerds, MD, MS⁴, Matt Kalaycio, MD⁵, Eric Kodish, MD⁶^*, Sudipto Mukherjee, MD, PhD⁴, Connie Cheng, PharmD, BCOP³^* and Mikkael A. Sekeres, MD, MS⁴

¹Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
²Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
³Leukemia Program, Department of Pharmacy, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
⁴Leukemia Program, Cleveland Clinic, Cleveland, OH
⁵Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁶Center for Ethics, Humanities and Spiritual Care, Cleveland Clinic, Cleveland, OH

11:45 AM

636

Increasing Cross-Referral and Recruitment to Clinical Trials: A New Approach

Roslyn Ristuccia, BSc MMedSc¹^*, Xavier C Badoux, MBBS¹, Melinda Gibson, BAppS MHSc¹^*, Admir Huseincehajic, BSc²^*, Judith Trotman, MBChB³ and Haematology Clinical Research Network⁴^*

¹Department of Haematology, St George Hospital, Kogarah, Australia
²Department of Haematology, Concord Repatriation General Hospital, Concord, Australia
³Department of Hematology, Concord Repatriation General Hospital, Concord, NSW, Australia
⁴Haematology Clinical Research Network NSW and ACT, Sydney, Australia

See more of: Health Services and Outcomes Research – Malignant Diseases
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

902.O4.6 902. Health Services and Outcomes Research – Malignant Diseases: Clinical Trials and Health Outcomes